Royalty Pharma Deal History & Licensing Activity
Royalty Pharma is a large biotech headquartered in US. Over the past three years, Royalty Pharma has been involved in 5 licensing and acquisition transactions, with a primary focus on Antibodies (4 deals).
Deals (12mo)
3
Active Trials
0
Top Modality
Antibodies
Focus Area
Immunology
Royalty Pharma Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Royalty Pharma in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| daraxonrasib | Revolution Medicines | Small Molecules | Phase 3 | license | Jul 10, 2026 |
| JNJ-4804 | Royalty Pharma plc | Other | Unknown | co development | Mar 30, 2026 |
| TEV-53408 | Teva Pharmaceuticals | Antibodies | Phase 2 | license | Jan 15, 2026 |
Royalty Pharma Pipeline Focus
Therapeutic areas and modalities where Royalty Pharma is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Royalty Pharma Strategic Signals
Key indicators of Royalty Pharma's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Royalty Pharma's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Immunology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Dermatology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for dermatology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Royalty Pharma Licensing & Deal Activity
Royalty Pharma is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, Royalty Pharma ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Royalty Pharma include Immunology (4 deals and trials), Mega Deals (2 deals and trials), and Dermatology (2 deals and trials). In terms of modality, Royalty Pharma has shown particular interest in antibodies, small molecules, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Royalty Pharma and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Royalty Pharma's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.